Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary frequency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Urinary frequency. Displaying page 6 of 22.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2017-003293-14 Sponsor Protocol Number: RVT-901-3003 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overa...
    Medical condition: Adult men and women with either: •OAB Wet • OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) BG (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024179-18 Sponsor Protocol Number: A0221094 Start Date*: 2011-05-31
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DE (Completed) CZ (Completed) FI (Completed) GR (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000956-25 Sponsor Protocol Number: 15-06 Start Date*: 2018-11-09
    Sponsor Name:Cook MyoSite, Incorporated
    Full Title: CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontin...
    Medical condition: Female Stress Urinary Incontinence
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003772-31 Sponsor Protocol Number: IT001-302 Start Date*: 2018-12-07
    Sponsor Name:Iterum Therapeutics International Limited
    Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe...
    Medical condition: Complicated urinary tract infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005215-17 Sponsor Protocol Number: 905-EC-007 Start Date*: 2009-09-14
    Sponsor Name:Astellas Pharma Europe Limited
    Full Title: A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor O...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) SE (Completed) IT (Completed) SK (Completed) GB (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006451-39 Sponsor Protocol Number: A0221046 Start Date*: 2008-02-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) LT (Completed) ES (Completed) HU (Completed) GR (Completed) EE (Completed) LV (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000192-42 Sponsor Protocol Number: 191622-516 Start Date*: 2007-07-25
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified N...
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) PT (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004844-27 Sponsor Protocol Number: SURE-01 Start Date*: 2021-06-01
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-01_An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cispl...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007293 Carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004876-16 Sponsor Protocol Number: SURE-02 Start Date*: 2021-11-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-ba...
    Medical condition: muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002776-14 Sponsor Protocol Number: 97 Start Date*: 2013-03-15
    Sponsor Name:University of Oslo, Faculty of medicine, Institute of Health and Society
    Full Title: Ibuprofen versus mecillinam for uncomplicated cystitis in adult, non-pregnant women
    Medical condition: Uncomplicated cystitis in adult, non pregnant women, age 18-60.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10000699 Acute cystitis (excl in pregnancy) LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006538-33 Sponsor Protocol Number: ONO-8539POE004 Start Date*: 2009-03-23
    Sponsor Name:Ono Pharmaceutical Co. Ltd.
    Full Title: A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BL...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-003940-35 Sponsor Protocol Number: KF6010-02 Start Date*: 2017-05-22
    Sponsor Name:Grünenthal GmbH
    Full Title: Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain ...
    Medical condition: Bladder pain syndrome.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004857 10071166 Bladder pain syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001013-81 Sponsor Protocol Number: ProBaBle Start Date*: 2014-10-10
    Sponsor Name:Centro Hospitalar de São João, EPE
    Full Title: Treatment of Bladder Pain Syndrome with Onabotulinum toxin A
    Medical condition: Bladder Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10071166 Bladder pain syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004160-67 Sponsor Protocol Number: Protocol F1J-MC-SBCT (a) Start Date*: 2005-02-24
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women with Stress Urinary Incontinence
    Medical condition: stress urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005546-39 Sponsor Protocol Number: 905-EC-003 Start Date*: 2006-12-11
    Sponsor Name:Astellas Pharma Europe BV
    Full Title: SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACT...
    Medical condition: Solifenacin succinate is indicated for the relief of symptoms of urinary frequency, nocturia and urgency with or without incontinence, associated with overactive bladder 10059617
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) HU (Completed) CZ (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-002143-27 Sponsor Protocol Number: 1208.15 Start Date*: 2005-02-15
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (...
    Medical condition: Urge Urinary Incontinence (UUI)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005401-41 Sponsor Protocol Number: 905-EC-012 Start Date*: 2013-07-03
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warr...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) GB (Completed) SE (Completed) IE (Completed) BE (Completed) PT (Completed) NO (Completed) AT (Completed) FI (Completed) GR (Completed) HU (Completed) ES (Completed) SI (Completed) NL (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004984-55 Sponsor Protocol Number: Nutri-Vita-D001 Start Date*: 2012-05-04
    Sponsor Name:SOCIETA' ITALIANA DI NEFROLOGIA
    Full Title: Controlled randomised interventional trial on the use of 25-OH D vitamin in haemodialysis patients.
    Medical condition: chronic haemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029149 Nephropathies HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003842-18 Sponsor Protocol Number: A301223 Start Date*: 2014-04-24
    Sponsor Name:Erasmus MC
    Full Title: Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study.
    Medical condition: Neurogenic bladder function disease in spina bifida patients.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10030685 Open spina bifida LLT
    16.1 100000004850 10041531 Spina bifida without mention of hydrocephalus LLT
    16.1 100000004857 10029280 Neurogenic bladder, not otherwise specified LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000045-20 Sponsor Protocol Number: KMD 3213 IT-CL 0376 Start Date*: 2011-06-17
    Sponsor Name:RECORDATI S.p.A
    Full Title: Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study)
    Medical condition: Benign prostatic hyperplasia.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) HU (Completed) IE (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 13:59:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA